Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 25
Filtrar
1.
Physiol Meas ; 36(7): 1351-65, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-26015439

RESUMO

The biological response to stress originates in the brain but involves different biochemical and physiological effects. Many common clinical methods to assess stress are based on the presence of specific hormones and on features extracted from different signals, including electrocardiogram, blood pressure, skin temperature, or galvanic skin response. The aim of this paper was to assess stress using EEG-based variables obtained from univariate analysis and functional connectivity evaluation. Two different stressors, the Stroop test and sleep deprivation, were applied to 30 volunteers to find common EEG patterns related to stress effects. Results showed a decrease of the high alpha power (11 to 12 Hz), an increase in the high beta band (23 to 36 Hz, considered a busy brain indicator), and a decrease in the approximate entropy. Moreover, connectivity showed that the high beta coherence and the interhemispheric nonlinear couplings, measured by the cross mutual information function, increased significantly for both stressors, suggesting that useful stress indexes may be obtained from EEG-based features.


Assuntos
Encéfalo/fisiopatologia , Eletroencefalografia/métodos , Estresse Fisiológico/fisiologia , Estresse Psicológico/fisiopatologia , Adolescente , Adulto , Ritmo alfa/fisiologia , Artefatos , Ritmo beta/fisiologia , Eletroculografia , Humanos , Vias Neurais/fisiopatologia , Privação do Sono/fisiopatologia , Teste de Stroop , Adulto Jovem
2.
Int J Clin Pharmacol Ther ; 47(12): 726-32, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19954711

RESUMO

UNLABELLED: Low-molecular-weight heparins (LMWHs) are antithrombotic drugs that differ on biochemical and pharmacological properties. OBJECTIVE: This study was conducted to compare the pharmacodynamic time-course of two LMWHs, bemiparin and enoxaparin, at high prophylactic doses. METHODS: This was an open, randomized, single-blind, cross-over study to compare the pharmacodynamic time-course, safety and tolerability of two LMWHs, bemiparin 3500 IU and enoxaparin 4000 IU at subcutaneous single doses in 12 healthy male volunteers. Anti-Xa activity (main biomarker of heparin activity), anti-IIa activity, total and free tissue factor pathway inhibitor (TFPI), activated partial thromboplastin time (APTT), thrombin time (TT) and thromboplastin-thrombomodulin mediated time (Tp-TmT) were investigated. RESULTS: Bemiparin 3500 IU achieved more anti-Xa activity than enoxaparin 4000 IU, measured by the area under the curve (geometric mean AUC0t) (bemiparin 3.69 vs. enoxaparin 3.33 IU h/ml; p < 0.001). Maximum anti-Xa activity was reached at 3 hours and there were anti-Xa measurable levels up to 16 h after subcutaneous administration. Anti-Xa activity half-life was 5.44 hours for bemiparin and 4.71 hours for enoxaparin. Anti-IIa activity was above the limit of quantification (0.05 IU/ml) in only 2 volunteers after bemiparin and in 8 after enoxaparin. The "in-vivo" anti-Xa:IIa ratios were: bemiparin 37.9 (95% CI: 28.0 - 55.3, n = 2) and enoxaparin 16.3 (95% CI: 12.2 - 23.4, n = 8). Enoxaparin induced a higher release of total TFPI, but not on free TFPI, and a longer prolongation of APTT and TT (Emax) than bemiparin, with no differences between groups on Tp-TmT. Adverse events (one in each group) were mild and transient. CONCLUSION: Bemiparin 3500 IU showed more anti-Xa activity and higher anti-Xa: anti-IIa relationship than enoxaparin 4000 IU in healthy volunteers. Both treatments were well tolerated.


Assuntos
Anticoagulantes/farmacologia , Fatores de Coagulação Sanguínea/efeitos dos fármacos , Enoxaparina/farmacologia , Heparina de Baixo Peso Molecular/farmacologia , Adolescente , Adulto , Anticoagulantes/efeitos adversos , Anticoagulantes/farmacocinética , Testes de Coagulação Sanguínea , Estudos Cross-Over , Enoxaparina/efeitos adversos , Enoxaparina/farmacocinética , Heparina de Baixo Peso Molecular/efeitos adversos , Heparina de Baixo Peso Molecular/farmacocinética , Humanos , Masculino , Fatores de Tempo
3.
Clin Exp Pharmacol Physiol ; 36(5-6): 469-77, 2009 May.
Artigo em Inglês | MEDLINE | ID: mdl-19673928

RESUMO

1. The main objective of the present study was to compare the bioavailability/bioequivalence of a new prolonged-release (PR) formulation of torasemide with an immediate-release (IR) formulation. In addition, we assessed the pharmacokinetics of both formulations, as well as the urine pharmacodynamics. 2. Two doses (5 and 10 mg) of PR torasemide were compared with the same doses of IR torasemide in a single-blind, single-dose, two-treatment, two-period, cross-over, sequence-randomized clinical trial in 20 healthy volunteers (two groups; n = 10 in each group). Torasemide plasma concentrations were measured by high-pressure liquid chromatography-electrospray ionization mass spectrometry. Torasemide urine concentrations, the diuretic effect of torasemide, urine electrolytes and urine density were also determined. 3. Plasma bioequivalence parameters, based on logged values, were as follows: (i) in the 5 mg group, the area under the plasma drug concentration-time curve from t = 0 to last measurable drug concentration at time t (AUC(0-t)) tablet ratio was 1.03 (90% confidence interval (CI) 0.91-1.17) and C(max) was 0.82 (90% CI: 0.68-0.98); and (ii) in the 10 mg group, the AUC(0-t) was 1.07 (90% CI 0.99-1.14) and C(max) was 0.68 (90% CI 0.60-0.78). The PR formulation showed a significantly prolonged t(max) compared with the IR formulation. The amount of torasemide recovered in the urine 24 h after administration was higher with the PR formulation for both doses. The natriuretic rate versus torasemide excretion rate for the PR and IR formulations were successfully regressed to a sigmoid E(max) model. Pharmacodynamic urine evaluations were similar with both formulations, although urine volume and urine electrolyte excretion were lower for the PR formulation in the first hour after administration. However, the PR formulation showed higher natriuretic efficiency. No significant adverse events were reported. 4. In conclusion, both formulations of torasemide showed similar systemic exposure (AUC). However, the PR formulation had a lower rate of absorption (lower C(max) and prolonged t(max)). The PR formulation had urinary excretion rates that were associated with a higher natriuretic efficiency and more constant diuresis.


Assuntos
Sulfonamidas/administração & dosagem , Sulfonamidas/farmacocinética , Administração Oral , Adulto , Disponibilidade Biológica , Estudos Cross-Over , Preparações de Ação Retardada , Diuréticos/administração & dosagem , Diuréticos/sangue , Diuréticos/farmacocinética , Diuréticos/urina , Relação Dose-Resposta a Droga , Humanos , Masculino , Método Simples-Cego , Sulfonamidas/sangue , Sulfonamidas/urina , Equivalência Terapêutica , Torasemida , Adulto Jovem
4.
Fundam Clin Pharmacol ; 23(1): 115-25, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19267775

RESUMO

The major aim of the study was to compare the pharmacokinetic profile of repeated-dose administration of a prolonged-release (PR) formulation of torasemide with that of an immediate-release (IR) dosage. Sixteen volunteers received one daily dose, on four consecutive days, of 10 mg of torasemide-PR or torasemide-IR in a single-blind, two-treatment, two-period, repeated-dose, cross-over, sequence-randomized clinical trial. Blood samples were collected at various time points on day 1 (single-dose) and on day 4 (repeated-dose) and torasemide concentrations were analysed by LC/MS/MS. Diuretic effect and urine electrolytes were measured. Urinary urgency was subjectively assessed by visual analogue scales. Safety and tolerability were also determined. Based on logged values, bioequivalence parameters, were: on day 1, ratio = 1.07 (90% CI 1.02-1.1), C(max) ratio = 0.69 (90% CI 0.67-0.73); and on day 4, ratio = 1.02 (90% CI 0.98-1.05), C(max) ratio = 0.62 (90% CI 0.55-0.70). PR had longer t(max) than IR and showed significantly lower fluctuations of plasma concentrations. Urine evaluations were similar with both formulations, although PR showed a lower urine volume in the first hours post-administration. Episodes of acute urinary urgency occurred later and were subjectively less intensive with PR. No significant adverse events were reported.


Assuntos
Diuréticos/farmacocinética , Sulfonamidas/farmacocinética , Adulto , Área Sob a Curva , Cromatografia Líquida , Estudos Cross-Over , Preparações de Ação Retardada , Diuréticos/administração & dosagem , Diuréticos/efeitos adversos , Esquema de Medicação , Eletrólitos/urina , Feminino , Humanos , Masculino , Método Simples-Cego , Sulfonamidas/administração & dosagem , Sulfonamidas/efeitos adversos , Espectrometria de Massas em Tandem , Equivalência Terapêutica , Torasemida , Adulto Jovem
5.
Neuropsychobiology ; 55(3-4): 203-12, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17878744

RESUMO

BACKGROUND/AIMS: Benzodiazepines (BZDs) are the most effective of the psychotropic drugs in the treatment of anxiety disorders. Tolerance has been reported for the majority of BZDs after chronic administration. However, little attention has been paid to the possibility that tolerance might be present after the intermittent oral administration of BZDs. The objectives of the present study were to assess tolerance development after the administration of two intermittent single oral doses of alprazolam given 15 days apart in healthy volunteers, and to compare the results obtained using measures from different domains: neurophysiological, psychomotor and subjective. METHODS: Twenty-four healthy volunteers received 2 mg of alprazolam orally on two experimental days, 15 days apart. Plasma concentrations and pharmacodynamics (PD) were assessed before drug intake and at different times in the following 24 h. PD was assessed through EEG (relative alpha and relative beta-1 activities), cancellation task (total and correct number of responses) and visual analogue scales (activity and drowsiness). RESULTS: No differences were observed in the PKs of alprazolam between occasions. A proteresis was present in both administrations for impairments of psychomotor performance and relative beta-1 activity, whereas it was present only after the second administration for subjective assessments and relative alpha activity. The proteresis on the second occasion was higher than on the first one. CONCLUSIONS: The administration of two single oral doses of alprazolam, 2 weeks apart in healthy volunteers, yielded the same PKs on both occasions, but significant changes were observed in the PD profile. Acute tolerance was observed after the second administration. Two patterns of acute tolerance development were obtained: (1) impairments of psychomotor performance and relative beta-1 activity, and (2) subjective assessments and relative alpha activity.


Assuntos
Alprazolam/administração & dosagem , Tolerância a Medicamentos/fisiologia , Eletroencefalografia/efeitos dos fármacos , Hipnóticos e Sedativos/administração & dosagem , Desempenho Psicomotor/efeitos dos fármacos , Adolescente , Adulto , Alprazolam/sangue , Alprazolam/farmacocinética , Área Sob a Curva , Vias de Administração de Medicamentos , Estudos de Avaliação como Assunto , Feminino , Humanos , Hipnóticos e Sedativos/sangue , Hipnóticos e Sedativos/farmacocinética , Masculino , Testes Neuropsicológicos , Medição da Dor/métodos , Método Simples-Cego , Fatores de Tempo
6.
Vigilia sueño ; 18(supl.1): 26-31, sept. 2006. tab, ilus
Artigo em Espanhol | IBECS | ID: ibc-126581

RESUMO

La somnolencia es un acontecimiento frecuente y fisiológico en ciertas circunstancias. La somnolencia excesiva durante el día se caracteriza por una sensación anormal de sueño con fuerte tendencia a dormirse en situaciones o momentos inapropiados, que debe diferenciarse de la fatiga. Entre las posibles causas de una somnolencia excesiva diurna está el consumo de fármacos. Hay dos posibilidades por las que los fármacos pueden considerarse como agentes etiológicos: a) a través de un mecanismo indirecto (compuestos que alteran la cantidad y la calidad del sueño y condicionan su fragmentación o deprivación) o b) por un efecto directo que propicia de forma mediada un aumento de la somnolencia diurna. Este favorecimiento de la somnolencia diurna debería identificarse como reacción adversa. Se describen los nuevos términos que la investigación de los mecanismos implicados en el control de la sucesión de sueño-vigilia está introduciendo en la farmacología de los fármacos productores de sueño: hipnóticos, promotores del sueño, intensificadores del sueño, modificadores de la biestabilidad y cronobióticos. Se identifican los factores farmacocinéticos que principalmente determinan la duración del efecto hipnótico tras administración única (volumen de distribución) y tras administración múltiple (eliminación) y se expone la importante variación interindividual en la frecuencia e intensidad con que los fármacos inducen una somnolencia excesiva. Por último, se completa la visión del posible impacto de los fármacos sobre el ciclo sueño-vigilia refiriendo los posibles efectos durante la noche de los fármacos tomados por la mañana, enfatizando la importancia de considerar el proceso como un todo continuo y no como compartimentos estancos (AU)


In certain circumstances sleepiness is a frequent and physiological event. Excessive daytime sleepiness is characterized by an abnormal sleep sensation with a strong tendency to fall asleep in inappropriate situations and time moments, which should be differentiated from fatigue. Among the possible causes of excessive daytime sleepiness there is drug consumption. There are two different possibilities to consider drugs as etiological agents: a)thought an indirect mechanism (compounds disrupting sleep quantity and quality resulting in sleep fragmentation or deprivation) or b) by a straight effect directly promoting an increase of daytime sleepiness. This promotion of daytime sleepiness should be identified as an adverse reaction. The new terms that research on the mechanisms which control the wake-sleep cycle is introducing in the pharmacology of drugs favouring sleep are described: hypnotics, sleep promoters, sleep enhancers, bi-stability modifiers and chronobiotics. The pharm acokinetic factors which mainly determine the duration of the hypnotic effects are identified, either after a single administration (volume of distribution) or after a repetitive administration (elimination) and the important interindividual variation in frequency and intensity of drug induced excessive sleepiness is explained. Lastly, the description of the potential drug impact on the wake-sleep cycle is completed by referring thee ventual effects that drug ingestion at morning time could induce during the night, highlighting the importance to consider the process as a continuum non-compartmental one (AU)


Assuntos
Humanos , Masculino , Feminino , Fases do Sono , Distúrbios do Sono por Sonolência Excessiva/induzido quimicamente , Distúrbios do Sono por Sonolência Excessiva/complicações , Hipnóticos e Sedativos/metabolismo , Hipnóticos e Sedativos/farmacologia , Hipnóticos e Sedativos/uso terapêutico , Distúrbios do Início e da Manutenção do Sono/complicações , Sono , Fadiga/complicações , Fadiga/diagnóstico , /complicações
7.
Clin EEG Neurosci ; 37(2): 108-20, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16733942

RESUMO

A drug interaction refers to an event in which the usual pharmacological effect of a drug is modified by other factors, most frequently additional drugs. When two drugs are administered simultaneously, or within a short time of each other, an interaction can occur that may increase or decrease the intended magnitude or duration of the effect of one or both drugs. Drugs may interact on a pharmaceutical, pharmacokinetic or pharmacodynamic basis. Pharmacodynamic interactions arise when the alteration of the effects occurs at the site of action. This is a wide field where not only interactions between different drugs are considered but also drug and metabolites (midazolam/alpha-hydroxy-midazolam), enantiomers (ketamine), as well as phenomena such as tolerance (nordiazepam) and sensitization (diazepam). Pharmacodynamic interactions can result in antagonism or synergism and can originate at a receptor level (antagonism, partial agonism, down-regulation, up-regulation), at an intraneuronal level (transduction, uptake), or at an interneuronal level (physiological pathways). Alternatively, psychotropic drug interactions assessed through quantitative pharmaco-EEG can be viewed according to the broad underlying objective of the study: safety-oriented (ketoprofen/theophylline, lorazepam/diphenhydramine, granisetron/haloperidol), strictly pharmacologically-oriented (benzodiazepine receptors), or broadly neuro-physiologically-oriented (diazepam/buspirone). Methodological issues are stressed, particularly drug plasma concentrations, dose-response relationships and time-course of effects (fluoxetine/buspirone), and unsolved questions are addressed (yohimbine/caffeine, hydroxizyne/alcohol).


Assuntos
Mapeamento Encefálico/métodos , Encéfalo/efeitos dos fármacos , Interações Medicamentosas , Eletroencefalografia/métodos , Psicotrópicos/farmacologia , Tolerância a Medicamentos , Eletroencefalografia/efeitos dos fármacos , Humanos
8.
Methods Find Exp Clin Pharmacol ; 27(4): 227-34, 2005 May.
Artigo em Inglês | MEDLINE | ID: mdl-16082423

RESUMO

Eberconazole is a topical imidazole derivative, which has shown high potency against dermatophytes and yeasts (several species of Candida, Malassezia) in vitro and in experimental models. Clinical trials have found that the compound has a high degree of efficacy against dermatophytes and good tolerability. Evaluation of its a) topical and general tolerability, b) eventual development of sensitisation, c) local availability, and d) degree of systemic absorption. Two clinical trials with 28 healthy young volunteers of both sexes were performed. In Study I, placebo or eberconazole cream (2%) were applied at increasing doses: day 1 (0.5 g), days 2-3 (1 g), days 4-5 (2 g), days 6-7 (4 g), days 8-9 (8 g), and days 10-11 (12 g). On day 1, each application area was washed with ethanol-soaked gauzes at different times to assess availability of the active compound. In Study II, eberconazole cream (1%) was applied on day 1 and again at least one week later. After the first application, blood and urine samples were obtained at different times to assess systemic absorption. The only change observed was slight redness in a few volunteers after both active and placebo applications. This remitted spontaneously without intervention and we were able to continue with the administration of repeated increasing-doses. A few participants described side effects; these were all of mild intensity, and occurred in areas where placebo or eberconazole were applied, mainly within the first hour postapplication. The most frequent effect after the first application was coldness, and after repeated increasing-doses there was itching. No signs or symptoms of skin reactivity were observed following reexposure to the product. No clinically relevant changes were observed in vital signs (systolic and diastolic blood pressure, heart rate, body temperature), ECG, or analytical parameters (clinical haematology and biochemistry). The quantity of compound collected through washing gauzes decreased progressively over time. Plasma and urine concentrations of eberconazole were below the quantification limit of the analytical method (5 ng/ml) at all times. Eberconazole cream is a topical antimycotic drug that has good local and general tolerability. It has acceptable topical availability, no detectable systemic drug levels, and does not appear to cause skin sensitivity.


Assuntos
Antifúngicos/farmacologia , Antifúngicos/farmacocinética , Cicloeptanos/farmacologia , Cicloeptanos/farmacocinética , Imidazóis/farmacologia , Imidazóis/farmacocinética , Administração Tópica , Adulto , Antifúngicos/efeitos adversos , Disponibilidade Biológica , Cicloeptanos/efeitos adversos , Hipersensibilidade a Drogas/etiologia , Feminino , Humanos , Imidazóis/efeitos adversos , Masculino , Absorção Cutânea
9.
J Pharm Pharmacol ; 56(4): 471-6, 2004 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15099442

RESUMO

The pharmacokinetics/tolerability of lanreotide Autogel have been evaluated. Healthy volunteers (n = 24) first received immediate-release lanreotide as a single subcutaneous (s.c.) injection. After two days, 40 or 60 mg lanreotide Autogel was injected subcutaneously. Blood was sampled at various intervals for 56 days. Systemic/local adverse events and changes in biological profile/vital signs were recorded. Lanreotide Autogel produced a prolonged-release pharmacokinetic profile: mean area under the serum concentration-time curve from time 0 to infinity (AUC) was 53.73 +/- 8.99 and 79.48 +/- 13.06 ng mL(-1) day for 40 and 60 mg, respectively, mean peak serum concentration (C(max)) was 4.38 +/- 2.91 and 5.71 +/- 3.52 ng mL(-1), respectively, median time to reach C (minimum-maximum) was 0.50 (0.083-18.0) and 0.38 (0.083-9.01) days, respectively, mean apparent elimination half-life was 21.63 +/- 9.42 and 22.01 +/- 9.87 days, respectively, and relative bioavailability was 0.93 +/- 0.12 and 0.82 +/- 0.15, respectively. Thus, lanreotide Autogel exhibited linear pharmacokinetics for the doses studied. Pharmacokinetic profiles were similar in both genders, apart from statistically significant differences in C(max) and C(max)/AUC. The Autogel formulation of lanreotide was well tolerated, with systemic adverse events being mild/moderate. Erythema and a painless subcutaneous induration were the most common local adverse events. Lanreotide Autogel provided a prolonged dosing interval and good tolerability for treating acromegaly and carcinoid syndrome.


Assuntos
Antineoplásicos/farmacocinética , Peptídeos Cíclicos/farmacocinética , Somatostatina/farmacocinética , Adolescente , Adulto , Antineoplásicos/administração & dosagem , Antineoplásicos/efeitos adversos , Área Sob a Curva , Preparações de Ação Retardada , Feminino , Meia-Vida , Humanos , Injeções Subcutâneas , Masculino , Taxa de Depuração Metabólica , Peptídeos Cíclicos/administração & dosagem , Peptídeos Cíclicos/efeitos adversos , Somatostatina/administração & dosagem , Somatostatina/efeitos adversos , Somatostatina/análogos & derivados
10.
Int Arch Allergy Immunol ; 132(3): 263-7, 2003 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-14646388

RESUMO

OBJECTIVE: The aim of this double-blind, randomized, crossover, placebo-controlled clinical trial was to compare the inhibition of the histamine-induced skin reaction induced by ebastine 20 mg with respect to that induced by fexofenadine 120 mg or placebo. METHODS: Eighteen volunteers (10 males, 8 females) received the three treatments once daily for 5 days, with a mean 7-day washout period between treatments. Intradermal tests, using 0.05 ml from a solution containing 100 microg/ml of histamine, were performed at baseline and at 1, 1.5, 2, 3, 10 and 24 h after a single dose and repeated 5-day dose, and in addition after 34, 48, 58 and 72 h after repeated 5-day dose. RESULTS: After 24 h of acute administration, ebastine 20 mg was significantly more effective than fexofenadine 120 mg in reducing the wheal and flare induced by histamine challenge (p<0.001). Although fexofenadine 120 mg had the shortest onset of action (1.5 vs. 3 h in ebastine 20 mg), the duration of its antihistamine effect was the shortest (24 vs. 58 h in ebastine 20 mg) and wheal reduction after 24 h was not significantly different from placebo. The overall effect after single and repeated 5-day dose, expressed as the AUC of reduction of wheal and flare area (%/h), showed the following order of magnitude: ebastine 20 mg>fexofenadine 120 mg>placebo. No significant differences in the incidence of adverse events were found between the three treatments. CONCLUSIONS: The present results clearly show a superior and long-acting effect of ebastine 20 mg compared with fexofenadine 120 mg on the skin response to histamine 24 h after dosing.


Assuntos
Butirofenonas/farmacologia , Antagonistas dos Receptores Histamínicos/farmacologia , Piperidinas/farmacologia , Pele/efeitos dos fármacos , Terfenadina/análogos & derivados , Terfenadina/farmacologia , Administração Oral , Adolescente , Adulto , Butirofenonas/administração & dosagem , Butirofenonas/efeitos adversos , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Piperidinas/administração & dosagem , Piperidinas/efeitos adversos , Pele/imunologia , Terfenadina/administração & dosagem , Terfenadina/efeitos adversos
11.
Nucl Med Commun ; 24(6): 679-82, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12766604

RESUMO

Chronic rejection is the most important cause of renal graft dysfunction. Non-immunological mechanisms have been suggested as a probable origin of chronic graft rejection, provoking a decrease in renal mass function, followed by glomerular hyperfiltration in the remnant nephrons, which could cause progressive glomerulosclerosis and functional loss. Early, or preclinical, identification of patients with glomerular hyperfiltration, defined as an increase in glomerular filtration fraction (GFF) and in glomerular capillary pressure (GCP), could prolong graft life. The objective of this study was to evaluate, non-invasively, stable renal graft haemodynamia and early glomerular hyperfiltration. We studied 116 renal transplant patients with stable renal function and five healthy living kidney donors with normal renal function. Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were determined using 51Cr-EDTA and o-[131I]iodohippurate, respectively. GFF was obtained from the relation between GFR and ERPF, and GCP from a mathematical model (Hall-Gomez' formula). A simultaneous analysis of renal function was performed. In transplant patients, the GFR and ERPF were significantly lower than in healthy, living, kidney donors (P<0.02). The same trend was observed for GCP (P<0.01), while GFF was not significantly different. Twelve patients (10.3%) had criteria of glomerular hyperfiltration. In patients without criteria of glomerular hyperfiltration, plasma level and clearance of creatinine were 128+/-33 micromol.l-1 and 56+/-15 ml.min-1, respectively; and in those patients with glomerular hyperfiltration criteria were 108+/-18 micromol.l-1 (P=NS) and 83+/-24 ml.min-1 (P=0.002) respectively. It is concluded that determinations of GFR, ERPF, GFF and GCP allow non-invasive evaluation of renal graft haemodynamia and can be useful in the early detection of glomerular hyperfiltration.


Assuntos
Ácido Edético , Taxa de Filtração Glomerular , Ácido Iodoipúrico , Transplante de Rim , Rim/diagnóstico por imagem , Rim/cirurgia , Fluxo Plasmático Renal , Adulto , Radioisótopos de Cromo , Feminino , Humanos , Radioisótopos do Iodo , Rim/irrigação sanguínea , Rim/fisiopatologia , Testes de Função Renal/métodos , Masculino , Pessoa de Meia-Idade , Cintilografia , Compostos Radiofarmacêuticos , Circulação Renal , Reprodutibilidade dos Testes , Sensibilidade e Especificidade
13.
Methods Find Exp Clin Pharmacol ; 24 Suppl C: 67-83, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12575490

RESUMO

Utilizing computer-assisted quantitative analysis of the electroencephalogram (EEG) in combination with certain statistical procedures and under specific design conditions, it is possible to objectively evaluate the functional bioavailability of psychotropic substances in the target organ: the human brain. Specifically, one may determine whether a drug is active in the central nervous system (CNS) compared with placebo in humans, the dose effect (including nonmonotonic drug effects along the continuum range of concentrations) and the time effect (including time-dependent pharmacodynamic phenomena as tolerance and sensitization), as well as its activity in relation to the formulation and route of application. Methodological aspects are introduced, discussing the usefulness of evaluating different treatments, doses, time points, states, target variables, electrodes and even different groups. Several issues are raised in relation to acute vs. repetitive administration, particularly those dealing with statistical comparisons when making conclusions about acute, repetitive or superimposed effects, and in relation to human psychotropic interactions, such as mechanistic drug-drug interaction descriptions, drug metabolites and enantiomers, as well as the importance of acquiring drug plasma concentrations, elapse of time and topographic distributions to accurately identify its occurrence. PK-PD modeling is introduced as a tool to enlarge the scope of inferences that can be derived when using pharmaco-EEG. The examples presented in order to develop the arguments are mainly focused on anxiolytic compounds belonging to the different neurochemical groups, benzodiazepines and azaspirones. Questions that have yet to been resolved are also addressed.


Assuntos
Ansiolíticos/administração & dosagem , Ansiolíticos/farmacocinética , Eletroencefalografia/efeitos dos fármacos , Modelos Biológicos , Interações Medicamentosas/fisiologia , Eletroencefalografia/métodos , Eletroencefalografia/estatística & dados numéricos , Humanos
14.
Psychopharmacology (Berl) ; 157(4): 358-67, 2001 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11605094

RESUMO

RATIONALE: The "fear-potentiated startle" paradigm has been extensively used in animal studies, and more recently in human experimental psychopharmacology to evaluate the effects of anxiogenic and anxiety-relieving drugs. Previous human studies have shown that both the baseline and the fear-potentiated responses can be inhibited by anxiety-relieving drugs, suggesting drug activity on two different emotional states, the former reflecting a resting condition and the latter more akin to pathological anxiety. OBJECTIVES: To examine to which extent the reductions induced by a benzodiazepine on the basic and the fear-potentiated startle responses are of equal intensity, and whether or not the drug shows a predominant, i.e., selective, effect on either. METHODS: The effects of three increasing doses of the benzodiazepine alprazolam (0.25, 0.5, and 1.0 mg) were assessed on the human baseline and fear-potentiated startle responses. Twelve healthy volunteers attended the laboratory on four experimental days and received either alprazolam or placebo according to a double-blind crossover balanced design. Startle recordings were undertaken 2 h after drug intake. Fear potentiation was implemented by means of an electric-shock-anticipation experimental procedure. Additionally, subjective self-reports of sedation and anxiety and psychomotor performance were obtained at 2 and 3 h, respectively, after drug administration. RESULTS: Alprazolam dose-dependently impaired psychomotor performance and produced increases in subjective anxiolytic activity and sedation, although the latter did not reach statistical significance. Additionally, the drug reduced the magnitude of the startle response both in the absence and in the presence of a threat-related cue, although a differentially greater inhibitory effect was seen on the fear-potentiated response as the dose increased. CONCLUSIONS: Alprazolam showed a greater inhibitory effect on the fear-potentiated startle than on the baseline reflex, suggesting a more selective action of the drug on those structures mediating potentiation of the behavioral response by anxiety.


Assuntos
Alprazolam/farmacologia , Ansiolíticos/farmacologia , Medo/psicologia , Reflexo de Sobressalto/efeitos dos fármacos , Estimulação Acústica , Adulto , Alprazolam/sangue , Ansiolíticos/sangue , Piscadela/efeitos dos fármacos , Estudos Cross-Over , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Humanos , Masculino , Desempenho Psicomotor/efeitos dos fármacos , Tempo de Reação/efeitos dos fármacos
15.
Clin Pharmacokinet ; 40(4): 245-62, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11368291

RESUMO

Dexketoprofen trometamol is a water-soluble salt of the dextrorotatory enantiomer of the nonsteroidal anti-inflammatory drug (NSAID) ketoprofen. Racemic ketoprofen is used as an analgesic and an anti-inflammatory agent, and is one of the most potent in vitro inhibitors of prostaglandin synthesis. This effect is due to the (S)-(+)-enantiomer (dexketoprofen), while the (R)-(-)-enantiomer is devoid of such activity. The racemic ketoprofen exhibits little stereoselectivity in its pharmacokinetics. Relative bioavailability of oral dexketoprofen (12.5 and 25mg, respectively) is similar to that of oral racemic ketoprofen (25 and 50mg, respectively), as measured in all cases by the area under the concentration-time curve values for (S)-(+)-ketoprofen. Dexketoprofen trometamol, given as a tablet, is rapidly absorbed, with a time to maximum plasma concentration (tmax) of between 0.25 and 0.75 hours, whereas the tmax for the (S)-(+)-enantiomer after the racemic drug, administered as tablets or capsules prepared with the free acid, is between 0.5 and 3 hours. The drug does not accumulate significantly when administered as 25mg of free acid 3 times daily. The profile of absorption is changed when dexketoprofen is ingested with food, reducing both the rate of absorption (tmax) and the maximal plasma concentration. Dexketoprofen is strongly bound to plasma proteins, particularly albumin. The disposition of ketoprofen in synovial fluid does not appear to be stereoselective. Dexketoprofen trometamol is not involved in the accumulation of xenobiotics in fat tissues. It is eliminated following extensive biotransformation to inactive glucuroconjugated metabolites. No (R)-(-)-ketoprofen is found in the urine after administration of dexketoprofen, confirming the absence of bioinversion of the (S)-(+)-enantiomer in humans. Conjugates are excreted in urine, and virtually no drug is eliminated unchanged. The analgesic efficacy of the oral pure (S)-(+)-enantiomer is roughly similar to that observed after double dosages of the racemic compound. At doses above 7mg, dexketoprofen was significantly superior to placebo in patients with moderate to severe pain. A dose-response relationship between 12.5 and 25mg could be seen in the time-effects curves, the superiority of the 25mg dose being more a result of an extended duration of action than of an increase in peak analgesic effect. A plateau in the analgesic activity of dexketoprofen trometamol at the 25mg dose is suggested. The time to onset of pain relief appeared to be shorter in patients treated with dexketoprofen trometamol. The drug was well tolerated.


Assuntos
Anti-Inflamatórios não Esteroides/farmacocinética , Cetoprofeno/farmacocinética , Anti-Inflamatórios não Esteroides/uso terapêutico , Biotransformação , Humanos , Cetoprofeno/uso terapêutico , Estereoisomerismo
16.
Psychopharmacology (Berl) ; 154(1): 85-95, 2001 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-11292011

RESUMO

RATIONALE: Ayahuasca is a South American psychoactive beverage that contains the naturally occurring psychedelic agent N,N-dimethyltryptamine (DMT). This "tea" has been used for centuries in religious and medicinal contexts in the rain forest areas of South America and is presently gaining the attention of psychedelic users in North America and Europe. OBJECTIVES: In the present study, the psychological effects and tolerability of ayvahuasca were assessed. METHODS: Three increasing doses of encapsulated freeze-dried ayahuasca (0.5, 0.75, and 1.0 mg DMT/kg body weight) were administered to six healthy male volunteers with prior experience in the use of this tea, in a single-blind crossover placebo-controlled clinical trial. RESULTS: Ayahuasca produced significant dose-dependent increases in five of the six subscales of the Hallucinogen Rating Scale, in the LSD, MBG, and A scales of the Addiction Research Center Inventory, and in the "liking", "good effects" and "high" visual analogue scales. Psychological effects were first noted after 30-60 min, peaked between 60-120 min, and were resolved by 240 min. The tea was well tolerated from a cardiovascular point of view, with a trend toward increase for systolic blood pressure. Modified physical sensations and nausea were the most frequently reported somatic-dysphoric effects. The overall experience was regarded as pleasant and satisfactory by five of the six volunteers, while one volunteer experienced an intensely dysphoric reaction with transient disorientation and anxiety at the medium dose and voluntarily withdrew from the study. CONCLUSIONS: Ayahuasca can be described as inducing changes in the perceptual, affective, cognitive, and somatic spheres, with a combination of stimulatory and visual psychoactive effects of longer duration and milder intensity than those previously reported for intravenously administered DMT.


Assuntos
Alucinógenos/farmacologia , N,N-Dimetiltriptamina/farmacologia , Plantas/química , Adulto , Alucinógenos/efeitos adversos , Hemodinâmica/efeitos dos fármacos , Humanos , Masculino , N,N-Dimetiltriptamina/efeitos adversos , Extratos Vegetais , Método Simples-Cego , América do Sul
17.
Clin Pharmacol Ther ; 66(5): 485-91, 1999 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-10579475

RESUMO

OBJECTIVE: To characterize the pharmacokinetic profile of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency. METHODS: Lanreotide was administered by intravenous bolus (7 microg/kg) to 12 patients with severe chronic renal insufficiency and to 12 healthy subjects. Lanreotide serum levels were determined by a radioimmunoassay procedure from time 0 until 24 hours after the administration. The main pharmacokinetic parameters were estimated by a noncompartmental treatment of data. RESULTS: The total serum clearance of lanreotide was found to be significantly lower in patients with severe chronic renal insufficiency than in healthy subjects (mean +/- SEM values of 0.138 +/- 0.017 L/hr/kg versus 0.244 +/- 0.027 L/hr/kg; P < .005). The initial lanreotide concentration, the elimination half-life, the area under the curve from time zero to 24 hours, and the area under the curve from time zero to infinity were significantly greater in patients with severe chronic renal insufficiency than in healthy subjects (307.45 +/- 79.19 ng/mL versus 127.18 +/- 22.65 ng/mL [P < .05]; 2.39 +/- 0.33 hours versus 1.32 +/- 0.20 hours [P < .005]; 62.55 +/- 9.73 ng/mL x hr versus 32.09 +/- 3.23 ng/mL x hr [P < .005]; and 62.95 +/- 9.78 ng/mL x hr versus 32.30 +/- 3.23 ng/mL x hr [P < .005], respectively). The initial volume of distribution, but not the volume of distribution at steady state, was significantly lower in patients with severe chronic renal insufficiency (0.040 +/- 0.008 L/kg versus 0.092 +/- 0.020 L/kg [P < .05] and 0.110 +/- 0.018 L/kg versus 0.172 +/- 0.046 L/kg [difference not statistically significant], respectively). The mean residence time was similar in both groups (0.77 +/- 0.06 hours versus 0.65 +/- 0.14 hours [difference not statistically significant]). CONCLUSIONS: A reduction in the total serum clearance and a decrease in the initial volume of distribution of lanreotide were observed in patients with severe chronic renal insufficiency treated with one intravenous bolus dose of 7 microg/kg lanreotide.


Assuntos
Anti-Inflamatórios não Esteroides/farmacocinética , Fármacos Gastrointestinais/farmacocinética , Falência Renal Crônica/sangue , Peptídeos Cíclicos/farmacocinética , Somatostatina/análogos & derivados , Adulto , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/sangue , Estudos de Casos e Controles , Feminino , Fármacos Gastrointestinais/administração & dosagem , Fármacos Gastrointestinais/sangue , Humanos , Injeções Intravenosas , Falência Renal Crônica/terapia , Masculino , Pessoa de Meia-Idade , Peptídeos Cíclicos/administração & dosagem , Peptídeos Cíclicos/sangue , Radioimunoensaio , Diálise Renal , Índice de Gravidade de Doença , Somatostatina/administração & dosagem , Somatostatina/sangue , Somatostatina/farmacocinética , Fatores de Tempo
18.
J Clin Pharmacol ; 38(S1): 33S-40S, 1998 12.
Artigo em Inglês | MEDLINE | ID: mdl-9882080

RESUMO

The pharmacokinetics of dexketoprofen trometamol were evaluated in two studies using healthy volunteers. In the first study, the relative bioavailability of a single oral capsule of dexketoprofen free acid 25 mg or dexketoprofen trometamol 25 mg (given as 37 mg of the trometamol salt) was compared to ketoprofen 50 mg in 18 healthy volunteers. In the second study, the pharmacokinetics and tolerability of oral dexketoprofen trometamol in tablet form were evaluated after either a single 25 mg dose (24 volunteers) or a repeated dose of 25 mg twice daily for 7 days (12 volunteers). The absorption of dexketoprofen from dexketoprofen trometamol capsules was bioequivalent to that of ketoprofen. On the other hand, the extent of absorption of dexketoprofen free acid was significantly lower than that for ketoprofen. Dexketoprofen trometamol showed the most rapid absorption rate, with highest Cmax and shortest t(max) values, whereas dexketoprofen free acid had the slowest absorption rate, and ketoprofen had an intermediate absorption rate. After repeated-dose administration of dexketoprofen trometamol, the pharmacokinetic parameters were similar to those obtained after single doses, indicating that no drug accumulation occurred. Dexketoprofen trometamol was well tolerated, with no clinically relevant adverse events reported.


Assuntos
Anti-Inflamatórios não Esteroides/farmacocinética , Cetoprofeno/análogos & derivados , Trometamina/análogos & derivados , Absorção , Administração Oral , Adulto , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/efeitos adversos , Disponibilidade Biológica , Estudos Cross-Over , Método Duplo-Cego , Feminino , Humanos , Cetoprofeno/farmacologia , Cetoprofeno/toxicidade , Masculino , Fatores Sexuais , Trometamina/farmacologia , Trometamina/toxicidade
19.
Brain ; 119 ( Pt 6): 2121-32, 1996 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-9010015

RESUMO

The contribution of dopaminergic systems to cognitive defects in Parkinson's disease and the cognitive effects of levodopa remain controversial. The levodopa plasma levels and the neuropsychological performance of 10 parkinsonian patients with a stable motor response to the drug and 10 matched parkinsonian patients with a 'wearing-off' phenomenon were studied 12 h after levodopa was withdrawn (time zero), and at 1 h and 4 h after an oral dose of levodopa (i.e. at '+1H' and '+4H'), to investigate whether discrete cognitive domains are more sensitive to levodopa in parkinsonian patients with the wearing-off phenomenon. Considering the 20 patients as a whole, levodopa significantly diminished the response time in verbal and visuospatial memory tests, the extradimensional matching test and the Wisconsin card sorting test (WCST), without significantly improving or worsening the patient's accuracy. A significant group-by-time effect was only evident in the WCST; while in stable patients levodopa produced no changes, wearing-off patients significantly reduced the number of categories achieved and had more perseverative errors at +1H, recovering at +4H. These results confirm previous findings of selective adverse effects of levodopa on highly demanding executive tasks in Parkinson's disease and additionally suggest that some previous discrepancies between studies may be accounted for by lack of differentiation between stable and wearing-off conditions. 'Frontal' disturbances on neuropsychological tests with levodopa may become evident only after massive degeneration of the dopamine systems has occurred.


Assuntos
Levodopa/farmacologia , Testes Neuropsicológicos , Doença de Parkinson/psicologia , Idoso , Feminino , Dedos , Humanos , Aprendizagem/efeitos dos fármacos , Levodopa/sangue , Levodopa/uso terapêutico , Masculino , Memória/efeitos dos fármacos , Pessoa de Meia-Idade , Doença de Parkinson/tratamento farmacológico , Desempenho Psicomotor/efeitos dos fármacos , Tempo de Reação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...